Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.| PharmaVoice
Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.| PharmaVoice
Precision BioSciences’ CEO discusses the company’s potentially groundbreaking cancer treatment.| PharmaVoice
Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.| PharmaVoice
Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.| PharmaVoice
Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.| PharmaVoice
Dupixent hasn’t generated as much buzz as top-sellers like Keytruda or Ozempic, but the drug is boosting Sanofi’s earnings into the future.| PharmaVoice
Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and could tee up an IPO.| PharmaVoice
Patent disputes in the U.S. and abroad have opened the door to new generics ready for launch as soon as September for BMS’ Sprycel.| PharmaVoice